TAK 915Alternative Names: TAK915
Latest Information Update: 06 Oct 2016
At a glance
- Originator Takeda
- Mechanism of Action Type 2 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Schizophrenia
Most Recent Events
- 01 Aug 2016 Takeda completes a phase-I trial in Schizophrenia (In volunteers) in USA (NCT02461160)
- 30 Apr 2016 Takeda completes a phase I trial in Healthy volunteers in USA (NCT02584569)
- 27 Oct 2015 Takeda plans a phase I trial in Healthy volunteers in USA (NCT02584569)